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Antibiotic Prevention for Maternal
Group B Streptococcal Colonization
on Neonatal GBS-Related Adverse
Outcomes: A Meta-Analysis
Shunming Li †, Jingya Huang †, Zhiyao Chen, Dan Guo, Zhenjiang Yao and Xiaohua Ye*
School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China
Maternal colonization with group B Streptococcus (GBS) during pregnancy increases the
risk of neonatal infection by vertical transmission. However, it remains unclear whether
treating all colonized women during labor exposes a large number of their neonates to
possible adverse effects without benefit. We performed a meta-analysis to assess the
effect of intrapartum antibiotic prophylaxis on neonatal adverse outcomes. We identified
studies by searching several English and Chinese electronic databases and reviewing
relevant articles. Data were pooled using fixed-effects or random-effects meta-analysis,
and for each outcome both risk ratio (RR) and 95% confidence intervals (95%
CIs) were calculated. Fourteen studies (2,051 pregnant women and 2,063 neonates)
were included, comprising 13 randomized clinical trials and 1 cohort study. Antibiotic
prophylaxis is associated with a significant reduced risk of all cause infections (RR= 0.28,
95% CI = 0.18–0.42), GBS infection (RR = 0.24, 95% CI = 0.13–0.44), early-onset
GBS infection (RR = 0.24, 95% CI = 0.13–0.45), non-GBS infections (RR = 0.34,
95% CI = 0.20–0.59), and GBS colonization (RR = 0.10, 95% CI = 0.06–0.16). But no
significant reduction was observed in late-onset GBS infection, mortality from early-onset
GBS infection or from non-GBS infections. Notably, no significant differences were found
between ampicillin and penicillin prevention for neonatal adverse outcomes. Our findings
suggest that antibiotic prophylaxis is effective in reducing neonatal GBS colonization and
infection.
Keywords: group B Streptococcus, infection, intrapartum antibiotic prophylaxis, clinical adverse outcomes,
meta-analysis
INTRODUCTION
Group B Streptococcus (GBS) is a significant cause of neonatal sepsis and meningitis and of severe
infections in pregnant women (Murayama et al., 2009). GBS is also a commensal that colonizes the
gastrointestinal and genitourinary tracts, resulting significant maternal and perinatal morbidity,
and can be transmitted from a GBS-colonized mother to her newborn via the ascending route
during labor and delivery, causing neonatal severe invasive diseases such as an early-onset GBS
(EOGBS) disease occurring within the first week and a late-onset GBS (LOGBS) disease occurring
between 1 week and 3 months of life (Borchardt et al., 2006; Huber et al., 2011; Stoll et al.,
2011; Okike et al., 2014). American Centers for Disease Control (CDC) had published three
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guidelines in the past 20 years (1996, 2002, and 2010) that
recommend the use of a risk-based or screening-based approach
to identify candidates for intrapartum antibiotic prophylaxis
(IAP; Centers for Disease Control and Prevention (CDC), 1996;
Schrag et al., 2002; Verani et al., 2010).
It is important to know if IAP does more good than harm
in trying to reduce mortality and morbidity from neonatal GBS
infection. However, the potential efficacy of IAP is not clear. A
few studies reported a significant inverse association between
IAP and neonatal GBS-related adverse outcomes (including GBS
infection and early-onset GBS infection), while other studies
found no significant association between the two (Matorras
et al., 1991; Gervasio et al., 2001; EI Helali et al., 2009; Li
and Meng, 2010). In addition, there were a few quantitative
reviews evaluated the efficacy of IAP for women with specific
diseases [preterm premature rupture of membranes (PROM) or
chorioamnionitis; (Egarter et al., 1996; Benitz et al., 1999)], but
the potential preventive effect for healthy women is still unclear.
Therefore, we systematically identified RCT and cohort studies
on the issue published up to April 2016, and carried out a meta-
analysis to explore the potential effect of intrapartum antibiotics
for maternal GBS colonization on neonatal adverse outcomes
(including GBS colonization, infection, and mortality).
METHODS
Search Strategy
The meta-analysis was conducted following the PRISMA
guidelines (Moher et al., 2010). Studies were identified through a
systematic search of MEDLIINE, PUBMED, WANGFANG, and
CNKI, from January 1979 to April 2016, using the following
searching terms: (“group B streptococcus” or “streptococcus
agalactiae”) and (“antibiotic” or “anti-bacterial agents” or
“intrapartum antibiotic prophylaxis”) and (“perinatal period” or
“pregnant women”). In addition, reference lists of all retrieved
articles and previous systematic reviews were checked for
further eligible publications. We restricted our search to studies
performed in human studies and published in English or
Chinese.
Inclusion and Exclusion Criteria
Two investigators (SM Li and JY Huang) independently reviewed
and assessed the eligibility of identified studies using the
following inclusion and exclusion criteria. The inclusion criteria
required studies to: (1) include original data from RCT or
cohort studies; (2) be based on pregnant women known to be
colonized with GBS in the vaginal/ intestinal tract and/or the
urinary tract at any time during the pregnancy; (3) provide
information on intrapartum use of antibiotics; (4) assess the
impact of antibiotics on clinical outcomes of neonates; and
(5) apply treatment or placebo explicitly and equally to both
treatment and control participants. Studies were excluded if they:
(1) were case reports, letters, abstracts, reviews, or meta-analyses;
(2) did not mention how many participants were allocated to
treatment or control group; and (3) administered intrapartum
treatment to both treatment group and control group. When
multiple articles reported the same study population, only the
most recent and informative study that met inclusion criteria was
included.
Outcomes of Interest
The outcomes of interest included: (1) neonatal mortality
(including all cause mortality, mortality from EOGBS infection
or infections caused by bacteria other than GBS); (2) neonatal
infection [including all cause infections, GBS infection, EOGBS
infection (symptoms and signs of sepsis or pneumonia in a
neonate born to a GBS positive mother, and positive GBS
bacterial cultures which from normally sterile body fluids
obtained from the neonate), LOGBS infection (infection due
to GBS in an infant at least seven days old), and infections
caused by bacteria other than GBS]; and (3) neonatal GBS
colonization (swabs sampled in external ear, nose, throat,
umbilicus, and rectum within 24 h of birth were cultured GBS
positive).
Data Extraction
Data extracted from each study included the name of the
first author, publication year, country, study design, population
source, number of participants, antibiotic use, and adverse
outcomes of neonates. Detailed information is shown in
Table 1 and Table S1. Two investigators (SM Li and JY
Huang) independently reviewed and cross-checked the data, and
disagreements were resolved by consensus.
Quality Assessment
For each study retained for the meta-analysis, we assessed
methodological quality based on following criteria: (1)
Randomized controlled trials were assessed using the Jadad
scale; and (2) non-RCTs were assessed using the Newcastle-
Ottawa quality assessment scale (NOS; Jadad et al., 1996; Wells
et al., 2011). The Jadad scale awards 1–5 points and RCTs
with ≥3 points are considered high-quality studies. The NOS
is categorized into three dimensions (including the selection
populations, comparability of groups, and outcome/exposure of
interest), and non-RCTs with ≥5 points indicate high-quality
studies.
Statistical Analysis
All statistical analyses were performed by using Stata statistical
software version 14.0 (Stata Corporation LP, College Station,
Texas, USA). All summary estimates of the relative ratio (RR)
were pooled by either fixed-effects model (P for heterogeneity
> 0.1) or random-effects model (P for heterogeneity ≤ 0.1;
Mantel and Haenszel, 1959; DerSimonian and Laird, 1986).
Heterogeneity among studies was tested by the chi-squared
test with the Cochrane Q statistic (significant at P ≤ 0.1) and
quantified by I2 statistic (Higgins and Thompson, 2002; Higgins
et al., 2003). The subgroup analysis was performed according
to maternal conditions (without infectious symptoms vs. with
probable infectious symptoms), study quality (high-quality vs.
low-quality), gestational ages (35–37 vs. 17–43 weeks) and
antibiotic prevention (ampicillin vs. penicillin), using χ2-tests
(significant at P ≤ 0.05).
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TABLE 1 | Main characteristics of studies in the meta-analysis.
Author, year Country Study design Quality indexa Antibiotic use Neonate
n1/n Adverse outcomes
b
Matorras et al., 1991 Spain RCT 2 AMP 60/121 NGBSC, EOGBSI, LOGBSI, NI
Gervasio et al., 2001 USA Cohort 7 PEN 345/451 EOGBSI,MGBSI,MI
EI Helali et al., 2009 France RCT 1 PEN 63/126 NGBSC,EOGBSI
Li and Meng, 2010 China RCT 1 PEN 136/227 NGBSC,EOGBSI
Yow et al., 1979 USA RCT 1 AMP 34/58 NGBSC
Easmon et al., 1983 British RCT 1 PEN / ERY 38/87 NGBSC
Lim et al., 1986 USA RCT 2 AMP 80/173 NGBSC,EOGBSI
Boyer and Gotoff, 1986 USA RCT 3 AMP 85/164 NGBSC,EOGBSI,LOGBSI,
MGBSI,MI
Tuppurainen and
Hallman, 1989
Finland RCT 2 PEN 88/199 EOGBSI
Shen et al., 2012 China RCT 1 PEN 91/117 NI
Ma et al., 2014 China RCT 1 PEN 68/98 NI
Bai, 2014 China RCT 2 PEN 33/65 NI
Zhang et al., 2015 China RCT 1 PEN 92/113 NI
Yang, 2015 China RCT 3 PEN 32/64 NI
n, number of participants; n1, number of participants in the treatment group; RCT: randomized controlled trial; AMP, ampicillin; PEN, penicillin; ERY, erythromycin;
aThe Newcastle-Ottawa scale was used in cohort studies, and the Jadad scale was used in RCTs.
bNGBSC, neonatal group B streptococcal colonization; EOGBSI, early-onset group B streptococcal infection; LOGBSI, late-onset group B streptococcal infection; MGBSI, mortality
from early-onset group B streptococcal infection; NI, neonatal infections; MI, neonatal mortality from infections caused by bacteria other than GBS.
RESULTS
Characteristics of Eligible Studies
The flowchart of literature search for meta-analysis was shown
in Figure 1. By reading the abstracts and using our criteria, 41
studies were selected for detailed evaluation; 30 studies were
excluded for the reasons noted in Figure 1. Three studies were
included through manual searches of the relevant systematic
reviews and reference list (Egarter et al., 1996; Benitz et al., 1999;
Ohlsson and Shah, 2014). Finally, 14 studies were included in
the final analysis (Yow et al., 1979; Easmon et al., 1983; Boyer
and Gotoff, 1986; Lim et al., 1986; Tuppurainen and Hallman,
1989; Matorras et al., 1991; Gervasio et al., 2001; EI Helali et al.,
2009; Li and Meng, 2010; Shen et al., 2012; Bai, 2014; Ma et al.,
2014; Yang, 2015; Zhang et al., 2015). The main characteristics of
eligible studies are given in Table 1 and the main characteristics
of participants are given in Table S1. There were 13 RCT studies
and one cohort study with a total of 2051 pregnant women and
2063 neonates. Six of these studies were conducted in China, four
were in USA and the rest were in Europe.
Study Quality
Thirteen manuscripts were RCTs. The maximum score in the
Jadad scale was three because it is difficult to have a double-
blind study in this field. Two studies received Jadad scores of 3,
four studies received 2, and seven studies received 1. The only
non-RCT study received NOS score of 7 (Table 1).
Antibiotic Prevention for Neonatal Mortality
The overall RRs of neonatal mortality for IAP were presented
in Figure 2. No statistically significant reduction was observed
in the incidence of all cause mortality (RR = 0.35, 95% CI =
0.05–2.78), mortality from EOGBS infection (RR = 0.51, 95%
CI = 0.06–4.55) or from non-GBS infections (RR = 0.31, 95%
CI = 0.01–7.50). There was no evidence of heterogeneity among
studies on all cause mortality (P = 0.469, I2 = 0%) and mortality
from EOGBS infection (P = 0.633, I2 = 0%).
Antibiotic Prevention for Neonatal Infection
The overall RRs of neonatal infection for IAP were presented
in Figure 3. Overall, there was a significant reduction in the
incidence of all cause infections (RR = 0.28, 95% CI = 0.18–
0.42), GBS infection (RR = 0.24, 95% CI = 0.13–0.44), EOGBS
infection (RR = 0.24, 95% CI = 0.13–0.45), and non-GBS
infections (RR = 0.34, 95% CI = 0.20–0.59) for antibiotic
prophylaxis. However, no statistically significant reduction was
observed in LOGBS infection (RR = 0.36, 95% CI = 0.01–8.69).
There was no evidence of heterogeneity among studies on all
cause infections (P = 0.892, I2 = 0%), GBS infection (P = 0.723,
I2 = 0%), EOGBS infection (P = 0.747, I2 = 0%), and non-GBS
infections (P = 0.840, I2 = 0%).
Antibiotic Prevention for Neonatal GBS
Colonization
The overall RRs of neonatal GBS colonization for IAP were
presented in Figure 4. There was a significant reduction in the
incidence of neonatal GBS colonization for antibiotic prophylaxis
(RR = 0.10, 95% CI = 0.06–0.16), with no evidence of
heterogeneity among studies (P = 0.184, I2 = 32.0%).
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FIGURE 1 | Flowchart of literature search for meta-analysis.
Comparison of Efficacy of Ampicillin and
Penicillin
In subgroup analysis by antibiotic prevention (ampicillin vs.
penicillin) for neonatal adverse outcomes (Table 2), we found
a similar efficacy in prevention of all cause mortality (RR =
0.19, 95% CI = 0.01–3.82, for ampicillin; RR = 0.93, 95% CI
= 0.04–22.61, for penicillin; P for difference = 0.474), all cause
infections (RR = 0.15, 95% CI = 0.04–0.48, for ampicillin; RR
= 0.32, 95% CI = 0.21–0.50, for penicillin; P for difference
= 0.272), and GBS colonization (RR = 0.08, 95% CI = 0.02–
0.27, for ampicillin; RR = 0.13, 95% CI = 95% CI = 0.05–0.33,
for penicillin; P for difference = 0.670) between two groups.
When differentiating adverse outcomes in GBS-related and other
bacteria related, there was still evidence of similar risks of
mortality from EOGBS infection (P for difference = 0.634), GBS
infection (P for difference = 0.199), EOGBS infection (P for
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FIGURE 2 | Summary relative risk of neonatal mortality for antibiotic
prophylaxis. The combined relative risk was achieved using fixed-effects
model. (GBS, group B Streptococcus; EOGBS, early-onset group B
streptococcal).
difference = 0.233), and non-GBS infections (P for difference
= 0.916) between two groups. The number of studies on other
outcomes was too small to perform subgroup analysis on.
Impact of Study Quality, Maternal
Condition, and Gestational Ages
In subgroup analysis by study quality (Table 3), we found a
similar efficacy in prevention of all cause infections (P for
difference = 0.789), GBS infection (P for difference = 0.474),
EOGBS infection (P for difference = 0.464), non-GBS infections
(P for difference= 0.349), and GBS colonization (P for difference
= 0.258) between two groups. The number of studies on other
outcomes was too small to perform subgroup analysis on. In
subgroup analysis by maternal conditions (Table 4), we found
a similar efficacy in prevention of all cause mortality (P for
difference = 0.474), mortality from EOGBS infection (P for
difference= 0.634), all cause infections (P for difference= 0.703),
GBS infection (P for difference = 0.566), EOGBS infection (P
for difference = 0.624), non-GBS infections (P for difference =
0.488), and GBS colonization (P for difference = 0.465) between
two groups. In subgroup analysis by gestational ages (Table 5),
we found a similar efficacy in prevention of all cause infections
(P for difference = 0.179), GBS infection (P for difference =
0.351), EOGBS infection (P for difference = 0.390), non-GBS
infections (P for difference = 0.279), and GBS colonization (P
for difference= 0.502) between two groups.
DISCUSSION
We contributed additionally to the literature by including more
new trials to explore the potential role of antibiotic prophylaxis
and differentiating neonatal adverse outcomes in GBS and non-
GBS related diseases to make neonatal adverse outcomes clearer.
This updated meta-analysis confirms that antibiotic prophylaxis
appears to significantly reduce the risk of neonatal adverse
outcomes, including all cause infections, GBS infection, EOGBS
infection, non-GBS infections, and GBS colonization.
There are two types of interventions that may reduce the risk
of neonatal GBS infection by vertical transmission, including for
high-risk (PROM, chorioamnionitis and so on) and moderate-
risk (vaginal GBS colonization, maternal fever, prematurity, and
low birth weight) mothers. Although evidence from two previous
meta-analyses indicated that antibiotic therapy significantly
reduced the risk of sepsis in infants born to women with PROM
and chorioamnionitis (Egarter et al., 1996; Benitz et al., 1999),
but the potential effect for moderate-risk women is still unclear.
A few available studies have explored the potential association
between intrapartum antibiotics for GBS-colonized women
and neonatal GBS-related infections, but current evidence is
inconsistent (Boyer and Gotoff, 1986; Tuppurainen andHallman,
1989; Shen et al., 2012; Ma et al., 2014). The only meta-
analysis (four trials) on intrapartum antibiotics for maternal GBS
colonization published so far indicated that incidence of EOGBS
infection was reduced with intrapartum antibiotics compared to
no treatment (Ohlsson and Shah, 2014). Our meta-analysis based
on 14 studies provides more reliable evidence that prophylactic
antibiotics for GBS-colonized women significantly reduce the
risk of all cause infections, GBS infection, EOGBS infection, and
non-GBS infections, indicating that antibiotic prophylaxis may
reduce the risk of bacteria vertical transmission (including GBS
isolates). Notably, only two RCTs conducted more than 20 years
ago and enrolling a total of 289 women have been published, and
as a result we found no significant reduction in LOGBS infection
in our meta-analysis study. These findings highlight the need for
further well designed and conducted RCTs to better understand
the potential effect of antibiotic prophylaxis on LOGBS infection.
The potential effect of antibiotic prophylaxis for GBS
colonized women on neonatal mortality remains unclear. It is
remarkable that previous evidence on the topic has been so
poorly studied, and only two studies enrolling a total of 615
women have been published (Boyer and Gotoff, 1986; Gervasio
et al., 2001). Our meta-analysis on these two studies revealed that
the use of intrapartum antibiotics did not significantly reduce
the incidence of mortality from EOGBS infection and mortality
from all causes. It is possible that the sample size was insufficient
for effective assessment of intrapartum antibiotics on such low
neonatal mortality (0.23% in treatment group, 1.08% in control
group, for all cause mortality; 0.23% in treatment group, 0.54%
in control group, for mortality from EOGBS infection; Gervasio
et al., 2001; Boyer and Gotoff, 1986). With a type I error of 0.05
and power of 80% and the above incidences, 1,640 women per
group and 6,894 women per group were required to detect a
significant difference in mortality from all causes and mortality
from EOGBS infection, respectively.
Neonatal GBS colonization is an important risk factor for the
morbidity and mortality of early-onset GBS disease. Prevention
of neonatal GBS colonization has been examined in several
previous studies, with reduced risk ranging from 0.01 to 0.22
(Yow et al., 1979; Easmon et al., 1983; Boyer and Gotoff, 1986;
Lim et al., 1986; Matorras et al., 1991; EI Helali et al., 2009; Li and
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FIGURE 3 | Summary relative risk of neonatal infections cause by GBS or bacteria other than GBS for antibiotic prophylaxis. The combined relative risk
was achieved using fixed-effects model. (GBS, group B Streptococcus; EOGBS, early-onset group B streptococcal; LOGBS, late-onset group B streptococcal).
Meng, 2010). Our study additionally contributes to the literature
by combining these inconsistent findings and indicated that
intrapartum antibiotics can prevent GBS vertical transmission
from colonized mothers to their infants (RR = 0.10 for neonatal
GBS colonization). Note that there are at least two mechanisms
by which neonatal colonization is prevented. First, numbers
of organisms in the mother’s vagina and rectum are reduced
temporarily so that the infant is delivered though a field that
is less contaminated by GBS. Second, the level of antibiotic
(ampicillin or penicillin) in the amniotic fluid remains high, so
the baby is bathed in a solution of antibiotic and he swallows the
fluid.
Information on whether intrapartum ampicillin is preferable
to penicillin for GBS colonized women is lacking. This study
compared the efficacy of ampicillin and penicillin prevention,
and found that ampicillin and penicillin are similarly effective in
prevention for neonatal GBS-related outcomes (including GBS
colonization, GBS infection, EOGBS infection, and mortality
from EOGBS infection), indicating that ampicillin may be an
acceptable alternative to penicillin for the prevention of neonatal
GBS-related diseases. As penicillin had a narrower spectrum of
antimicrobial activity and GBS continued to be susceptible to
it, penicillin was the chief choice for IAP, with ampicillin as an
acceptable alternative for the prevention of maternal infections.
Notably, the ORACLE trial revealed that the prescription of
amoxicillin–clavulanate or erythromycin for preterm labor (SPL)
women was associated with an increased risk of cerebral palsy
among their children at 7 years of age, supporting the opinion
that antibiotics are not advisable in SPL without clinical signs
of infection (Kenyon et al., 2008). Therefore, future studies
must direct more attention to exploring the long-term effect of
intrapartum antibiotics for neonatal adverse outcomes.
However, the increased use of intrapartum antibiotics to
prevent GBS diseases has raised public health concerns over
the emergence of antibiotic resistance among GBS strains.
Several studies have reported that erythromycin and clindamycin
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FIGURE 4 | Summary relative risk of neonatal group B streptococcal colonization for antibiotic prophylaxis. The combined relative risk was achieved using
fixed-effects model.
TABLE 2 | Effect comparison of subgroups of antibiotic prophylaxis.
Neonatal Subgroups of No. of RR(95%CI) Heterogeneity P-value for
outcomes antibiotics studies I2 (P-value) differencea
Mortality from all causes Ampicillin 1 0.19 (0.01, 3.82) – 0.474
Penicillin 1 0.93 (0.04,22.61) –
Mortality from EOGBSI Ampicillin 1 0.31 (0.01, 7.50) – 0.634
Penicillin 1 0.93 (0.04,22.61) –
Infection from all causes Ampicillin 3 0.15 (0.04, 0.48) 0.0% (0.768) 0.272
Penicillin 9 0.32 (0.21, 0.50) 0.0% (0.865)
GBS infection Ampicillin 3 0.10 (0.02, 0.51) 0.0% (0.984) 0.199
Penicillin 4 0.31 (0.16, 0.60) 0.0% (0.603)
EOGBSI Ampicillin 3 0.10 (0.02, 0.54) 0.0% (0.951) 0.233
Penicillin 4 0.31 (0.16, 0.60) 0.0% (0.603)
Infection from other bacteria other than GBS Ampicillin 1 0.36 (0.08, 1.72) – 0.916
Penicillin 5 0.34 (0.19, 0.60) 0.0% (0.726)
GBS colonization Ampicillin 4 0.08 (0.02, 0.27) 57.7% (0.069) 0.670
Penicillin 3 0.13 (0.05, 0.33) 0.0% (0.464)
GBS, Group B Streptococcus; EOGBSI, early-onset group B Streptococcal infection; RR, risk ratio; 95%CI, 95% confidence interval.
aChi-squared test was used to test the difference of subgroups.
resistance were the most common phenotypes (Jannati et al.,
2012; Bolukaoto et al., 2015; Goudarzi et al., 2015; Kuang et al.,
2015; Malek-Jafarian et al., 2015; Suhaimi et al., 2016). Since the
first CDC guideline had been published in 1996, the frequency of
erythromycin-resistant strains increased after a year (Lin et al.,
2000). Although previous studies had not reported resistance
to penicillin or ampicillin which was the first-line beta-lactam
antibiotics, GBS with reduced penicillin susceptibility had been
reported (Kimura et al., 2008; Jannati et al., 2012; Seki et al., 2015;
Suhaimi et al., 2016). On the other hand, the increasing resistance
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TABLE 3 | Effect comparison of subgroups of study quality.
Neonatal Subgroups of No. of RR(95%CI) Heterogeneity P-value for
outcomes study quality studies I2 (P-value) differencea
Infection from all causes High-quality 3 0.29 (0.11, 0.76) 0.0% (0.372) 0.789
Low-quality 9 0.28 (0.18, 0.44) 0.0% (0.884)
GBS infection High-quality 2 0.14 (0.03, 0.67) 0.0% (0.584) 0.474
Low-quality 5 0.27 (0.14, 0.52) 0.0% (0.584)
EOGBSI High-quality 2 0.14 (0.03, 0.67) 0.0% (0.584) 0.464
Low-quality 5 0.27 (0.14, 0.53) 0.0% (0.619)
Infection from bacteria other than GBS High-quality 1 0.60 (0.16, 2.30) – 0.349
Low-quality 5 0.30 (0.16, 0.55) 0.0% (0.881)
GBS colonization High-quality 1 0.19 (0.09, 0.37) – 0.258
Low-quality 6 0.07 (0.03, 0.14) 29.0% (0.218)
GBS, Group B Streptococcus; EOGBSI, early-onset group B Streptococcal infection; RR, risk ratio; 95%CI, 95% confidence interval.
aChi-squared test was used to test the difference of subgroups.
TABLE 4 | Effect comparison of subgroups of maternal conditions.
Neonatal Subgroups of No. of RR(95%CI) Heterogeneity P-value for
outcomes maternal condition studies I2 (P-value) differencea
Mortality from all causes Without infectious symptoms 1 0.19 (0.01, 3.82) – 0.474
With probable infectious symptoms 1 0.93 (0.04, 22.61) –
Mortality from EOGBSI Without infectious symptoms 1 0.31 (0.01, 7.50) – 0.634
With probable infectious symptoms 1 0.93 (0.04, 22.61) –
Infection from all causes Without infectious symptoms 6 0.25 (0.14, 0.45) 0.0% (0.658) 0.703
With probable infectious symptoms 6 0.31 (0.17, 0.57) 0.0% (0.807)
GBS infection Without infectious symptoms 5 0.26 (0.13, 0.50) 0.0% (0.519) 0.566
With probable infectious symptoms 2 0.16 (0.03, 0.80) 0.0% (0.746)
EOGBSI Without infectious symptoms 5 0.26 (0.13, 0.50) 0.0% (0.519) 0.624
With probable infectious symptoms 2 0.18 (0.04, 0.89) 0.0% (0.868)
Infection from bacteria other than GBS Without infectious symptoms 1 0.24 (0.08, 0.72) – 0.488
With probable infectious symptoms 5 0.37 (0.20, 0.70) 0.0% (0.813)
GBS colonization Without infectious symptoms 6 0.10 (0.06, 0.17) 41.6% (0.128) 0.465
With probable infectious symptoms 1 0.09 (0.02, 0.35) –
GBS, Group B Streptococcus; EOGBSI, early-onset group B Streptococcal infection; RR, risk ratio; 95%CI, 95% confidence interval.
aChi-squared test was used to test the difference of subgroups.
to the macrolides and clindamycin which used as alternative
drugs for penicillin allergic patients should be paid attention, and
guideline for these patients need to be further study (Bolukaoto
et al., 2015).
There are several potential limitations to this meta-analysis.
First, we did not attempt to search for unpublished studies,
believing that the rigor of the peer-review process guarantees the
quality of a published trial, which could bring the publication
bias. However, because not all trials are registered in public
databases, a reliable estimate of the publication bias is not
yet possible. Second, although statistical homogeneity did not
exist for all outcomes, the question of clinical homogeneity
is difficult to answer. There were differences in study design,
population source, gestational ages, maternal conditions, study
quality, and therapeutic regimens. However, the likelihood
should be small, because no significant heterogeneity was
observed in the subgroup analysis for gestational ages, maternal
conditions, and study quality. Third, only 2 (15.4%, 2/13) RCTs
are considered high-quality studies since it was difficult to
conduct a double blind RCT study in this field. Finally, pooling
of the English and Chinese literature together to extract the
relevant studies may bring language selection bias and increase
the heterogeneity of study participants. However, it brings
more eligible studies and thus more information for evaluating
the efficacy of IAP for neonatal GBS diseases, and there
was no evidence of heterogeneity among studies on neonatal
outcomes.
In conclusion, this meta-analysis shows that antibiotic
prophylaxis is effective in interrupting vertical transmission
of GBS and in reducing the incidence of GBS infections
(including EOGBS infection). However, the potential preventive
effectiveness of antibiotic prophylaxis to reduce neonatal LOGBS
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TABLE 5 | Effect comparison of subgroups of gestational ages.
Neonatal Subgroups of No. of RR(95%CI) Heterogeneity P-value for
outcomes gestational age studies I2 (P-value) differencea
Infection from all causes 35–37 weeks 7 0.34 (0.20, 0.57) 0.0% (0.755) 0.179
17–43 weeks 5 0.19 (0.09, 0.39) 0.0% (0.974)
GBS infection 35–37 weeks 4 0.28 (0.14, 0.57) 0.0% (0.488) 0.351
17–43 weeks 3 0.13 (0.03, 0.54) 0.0% (0.849)
EOGBSI 35–37 weeks 4 0.28 (0.14, 0.57) 0.0% (0.488) 0.390
17–43 weeks 3 0.14 (0.04, 0.57) 0.0% (0.865)
Infection from bacteria other than GBS 35–37 weeks 3 0.47 (0.21, 1.01) 0.0% (0.785) 0.279
17–43 weeks 3 0.25 (0.11, 0.55) 0.0% (0.816)
GBS colonization 35–37 weeks 5 0.06 (0.03, 0.14) 0.0% (0.117) 0.502
17–43 weeks 2 0.15 (0.08, 0.28) 0.0% (0.325)
GBS, Group B Streptococcus; EOGBSI, early-onset group B Streptococcal infection; RR, risk ratio; 95%CI, 95% confidence interval.
aChi-squared test was used to test the difference of subgroups.
infection and mortality from GBS infection is inconclusive, given
lack of evidence from well designed and conducted trials.
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